The role and research progress of Syndecan<b>-</b>1 in breast cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHUANG Haijiao , WANG Yingjie , NI Zhixin ,  ZHAO Song

Department of Breast Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, P. R. China;

Corresponding author：

ZHAO Song, Email: zhaosong998@126.com

Keywords：

breast cancer; Syndecan-1; proteoglycan; research progress

DOI：

10.7507/1007-9424.202203033

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective The results related to the role and research progress of Syndecan-1 in breast cancer are systematically reviewed, with the aim of providing new directions for the treatment and prognosis of breast cancer research. Method The unique properties and role of Syndecan-1 in breast cancer patients were analyzed and summarized by searching the relevant literatures in recent years. Results Syndecan-1 was of great significance in the diagnosis and treatment of breast cancer and could be used as a potential prognostic marker of breast cancer. Meanwhile, it could also be used as a potential therapeutic target for breast cancer, which had significant research value for clinical applications. Conclusion Syndecan-1 has been applied in the field of breast cancer research because of its unique properties and effects on the development, treatment and prognosis of breast cancer.

Citation： ZHUANG Haijiao, WANG Yingjie, NI Zhixin, ZHAO Song. The role and research progress of Syndecan-1 in breast cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(9): 1256-1260. doi: 10.7507/1007-9424.202203033 Copy

1.	Tuasha N, Petros B. Heterogeneity of tumors in breast cancer: implications and prospects for prognosis and therapeutics. Scientifica (Cairo), 2020, 2020: 4736091. doi: 10.1155/2020/4736091.
2.	DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin, 2019, 69(6): 438-451.
3.	Fan M, Xia P, Clarke R, et al. Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer. Nat Commun, 2020, 11(1): 4861. doi: 10.1038/s41467-020-18703-2.
4.	邵成良, 郑彬. 早产儿败血症患儿病原分布和真菌性败血症危险因素分析. 中国妇幼保健, 2022, 37(4): 654-657.
5.	Alghandour R, Ebrahim MA, Ghazy H, et al. Evaluation of the diagnostic and prognostic value of Syndecan-1 in acute leukemia patients. Cureus, 2020, 12(9): e10594. doi: 10.7759/cureus.10594.
6.	Valla S, Hassan N, Vitale DL, et al. Syndecan-1 depletion has a differential impact on hyaluronic acid metabolism and tumor cell behavior in luminal and triple-negative breast cancer cells. Int J Mol Sci, 2021, 22(11): 5874.
7.	Miše I, Vučić M. Comparison of Syndecan-1 immunohistochemical expression in lobular and ductal breast carcinoma with nodal metastases. Anal Cell Pathol (Amst), 2018, 2018: 9432375. doi: 10.1155/2018/9432375.
8.	赵晓雅, 马丛, 孙美玲, 等. 多配体蛋白聚糖-1细胞定位对人肝癌细胞侵袭的影响. 辽东学院学报(自然科学版), 2022, 29(1): 18-22.
9.	Nadanaka S, Bai Y, Kitagawa H. Cleavage of Syndecan-1 promotes the proliferation of the basal-like breast cancer cell line BT-549 via Akt SUMOylation. Front Cell Dev Biol, 2021, 9: 659428. doi: 10.3389/fcell.2021.659428.
10.	Kind S, Jaretzke A, Büscheck F, et al. A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. Mol Carcinog, 2019, 58(12): 2306-2315.
11.	Kim SY, Choi EJ, Yun JA, et al. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases. Int J Med Sci, 2015, 12(2): 92-99.
12.	Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis, 2009, 30(3): 397-407.
13.	Chute C, Yang X, Meyer K, et al. Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases. Breast Cancer Res, 2018, 20(1): 66. doi: 10.1186/s13058-018-0995-x.
14.	刘子祥, 张子艳, 周少波. Syndecan-1在恶性肿瘤浸润转移中的作用. 检验医学与临床, 2020, 17(1): 133-136.
15.	Szarvas T, Reis H, Kramer G, et al. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. Hum Pathol, 2014, 45(4): 674-682.
16.	Anttonen A, Leppä S, Ruotsalainen T, et al. Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 2003, 41(2): 171-177.
17.	Szarvas T, Sevcenco S, Módos O, et al. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. Urol Oncol, 2018, 36(6): 312.e9-312.e15.
18.	闻波, 陈佳伟, 王郑林, 等. 乙酰肝素酶与多配体蛋白聚糖-1在恶性肿瘤中的研究进展. 实用临床医药杂志, 2021, 25(13): 119-123.
19.	刘子祥, 周少波, 张子艳, 等. 沉默SDC1通过ERK信号通路促进胆囊癌细胞的侵袭和迁移. 现代肿瘤医学, 2021, 29(21): 3726-3731.
20.	Götte M, Kersting C, Ruggiero M, et al. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res, 2006, 26(1B): 621-627.
21.	Nassar E, Hassan N, El-Ghonaimy EA, et al. Syndecan-1 promotes angiogenesis in triple-negative breast cancer through the prognostically relevant tissue factor pathway and additional angiogenic routes. Cancers (Basel), 2021, 13(10): 2318. doi: 10.3390/cancers13102318.
22.	Pham SH, Pratt K, Okolicsanyi RK, et al. Syndecan-1 and -4 influence Wnt signaling and cell migration in human breast cancers. Biochimie, 2022, 198: 60-75.
23.	Moradpoor R, Salimi M. Crosstalk between tumor cells and immune System leads to epithelial-mesenchymal transition induction and breast cancer progression. Iran Biomed J, 2021, 25(1): 1-7.
24.	Gondelaud F, Ricard-Blum S. Structures and interactions of syndecans. FEBS J, 2019, 286(15): 2994-3007.
25.	Dubey R, van Kerkhof P, Jordens I, et al. R-spondins engage heparan sulfate proteoglycans to potentiate WNT signaling. Elife, 2020, 9: e54469. doi: 10.7554/eLife.54469.
26.	Wang Q, Yang L, Alexander C, et al. The niche factor syndecan-1 regulates the maintenance and proliferation of neural progenitor cells during mammalian cortical development. PLoS One, 2012, 7(8): e42883. doi: 10.1371/journal.pone.0042883.
27.	Rajkumar T, Amritha S, Sridevi V, et al. Identification and validation of plasma biomarkers for diagnosis of breast cancer in South Asian women. Sci Rep, 2022, 12(1): 100. doi: 10.1038/s41598-021-04176-w.
28.	Sheta M, Götte M. Syndecan-1 (CD138) as a pathogenesis factor and therapeutic target in breast cancer. Curr Med Chem, 2021, 28(25): 5066-5083.
29.	Nguyen TL, Grizzle WE, Zhang K, et al. Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer. Am J Clin Pathol, 2013, 140(4): 468-474.
30.	Scott E, Munkley J. Glycans as biomarkers in prostate cancer. Int J Mol Sci, 2019, 20(6): 1389. doi: 10.3390/ijms20061389.
31.	Wang X, He J, Zhao X, et al. Syndecan-1 suppresses epithelial-mesenchymal transition and migration in human oral cancer cells. Oncol Rep, 2018, 39(4): 1835-1842.
32.	Saleh ME, Gadalla R, Hassan H, et al. The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4⁺ T cell polarization in inflammatory and non-inflammatory breast cancer patients. PLoS One, 2019, 14(5): e0217550. doi: 10.1371/journal.pone.0217550.
33.	Agere SA, Kim EY, Akhtar N, et al. Syndecans in chronic inflammatory and autoimmune diseases: Pathological insights and therapeutic opportunities. J Cell Physiol, 2018, 233(9): 6346-6358.
34.	Bertrand J, Bollmann M. Soluble syndecans: biomarkers for diseases and therapeutic options. Br J Pharmacol, 2019, 176(1): 67-81.
35.	De Pasquale V, Pavone LM. Heparan sulfate proteoglycan signaling in tumor microenvironment. Int J Mol Sci, 2020, 21(18): 6588. doi: 10.3390/ijms21186588.
36.	Qiao W, Liu H, Guo W, et al. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol, 2019, 45(7): 1132-1137.
37.	Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer, 2003, 98(3): 474-483.
38.	Lim GH, Tan PH, Jara-Lazaro AR, et al. Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival. Singapore Med J, 2014, 55(9): 468-472.
39.	Tiemann K, Weigel MT, Alkatout I, et al. Significance of syndecan-1 expression in ductal carcinoma in situ of the breast. Anticancer Res, 2014, 34(7): 3607-3716.
40.	Conklin MW, Gangnon RE, Sprague BL, et al. Collagen alignment as a predictor of recurrence after ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev, 2018, 27(2): 138-145.

1. Tuasha N, Petros B. Heterogeneity of tumors in breast cancer: implications and prospects for prognosis and therapeutics. Scientifica (Cairo), 2020, 2020: 4736091. doi: 10.1155/2020/4736091.
2. DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin, 2019, 69(6): 438-451.
3. Fan M, Xia P, Clarke R, et al. Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer. Nat Commun, 2020, 11(1): 4861. doi: 10.1038/s41467-020-18703-2.
4. 邵成良, 郑彬. 早产儿败血症患儿病原分布和真菌性败血症危险因素分析. 中国妇幼保健, 2022, 37(4): 654-657.
5. Alghandour R, Ebrahim MA, Ghazy H, et al. Evaluation of the diagnostic and prognostic value of Syndecan-1 in acute leukemia patients. Cureus, 2020, 12(9): e10594. doi: 10.7759/cureus.10594.
6. Valla S, Hassan N, Vitale DL, et al. Syndecan-1 depletion has a differential impact on hyaluronic acid metabolism and tumor cell behavior in luminal and triple-negative breast cancer cells. Int J Mol Sci, 2021, 22(11): 5874.
7. Miše I, Vučić M. Comparison of Syndecan-1 immunohistochemical expression in lobular and ductal breast carcinoma with nodal metastases. Anal Cell Pathol (Amst), 2018, 2018: 9432375. doi: 10.1155/2018/9432375.
8. 赵晓雅, 马丛, 孙美玲, 等. 多配体蛋白聚糖-1细胞定位对人肝癌细胞侵袭的影响. 辽东学院学报(自然科学版), 2022, 29(1): 18-22.
9. Nadanaka S, Bai Y, Kitagawa H. Cleavage of Syndecan-1 promotes the proliferation of the basal-like breast cancer cell line BT-549 via Akt SUMOylation. Front Cell Dev Biol, 2021, 9: 659428. doi: 10.3389/fcell.2021.659428.
10. Kind S, Jaretzke A, Büscheck F, et al. A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. Mol Carcinog, 2019, 58(12): 2306-2315.
11. Kim SY, Choi EJ, Yun JA, et al. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases. Int J Med Sci, 2015, 12(2): 92-99.
12. Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis, 2009, 30(3): 397-407.
13. Chute C, Yang X, Meyer K, et al. Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases. Breast Cancer Res, 2018, 20(1): 66. doi: 10.1186/s13058-018-0995-x.
14. 刘子祥, 张子艳, 周少波. Syndecan-1在恶性肿瘤浸润转移中的作用. 检验医学与临床, 2020, 17(1): 133-136.
15. Szarvas T, Reis H, Kramer G, et al. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. Hum Pathol, 2014, 45(4): 674-682.
16. Anttonen A, Leppä S, Ruotsalainen T, et al. Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 2003, 41(2): 171-177.
17. Szarvas T, Sevcenco S, Módos O, et al. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. Urol Oncol, 2018, 36(6): 312.e9-312.e15.
18. 闻波, 陈佳伟, 王郑林, 等. 乙酰肝素酶与多配体蛋白聚糖-1在恶性肿瘤中的研究进展. 实用临床医药杂志, 2021, 25(13): 119-123.
19. 刘子祥, 周少波, 张子艳, 等. 沉默SDC1通过ERK信号通路促进胆囊癌细胞的侵袭和迁移. 现代肿瘤医学, 2021, 29(21): 3726-3731.
20. Götte M, Kersting C, Ruggiero M, et al. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res, 2006, 26(1B): 621-627.
21. Nassar E, Hassan N, El-Ghonaimy EA, et al. Syndecan-1 promotes angiogenesis in triple-negative breast cancer through the prognostically relevant tissue factor pathway and additional angiogenic routes. Cancers (Basel), 2021, 13(10): 2318. doi: 10.3390/cancers13102318.
22. Pham SH, Pratt K, Okolicsanyi RK, et al. Syndecan-1 and -4 influence Wnt signaling and cell migration in human breast cancers. Biochimie, 2022, 198: 60-75.
23. Moradpoor R, Salimi M. Crosstalk between tumor cells and immune System leads to epithelial-mesenchymal transition induction and breast cancer progression. Iran Biomed J, 2021, 25(1): 1-7.
24. Gondelaud F, Ricard-Blum S. Structures and interactions of syndecans. FEBS J, 2019, 286(15): 2994-3007.
25. Dubey R, van Kerkhof P, Jordens I, et al. R-spondins engage heparan sulfate proteoglycans to potentiate WNT signaling. Elife, 2020, 9: e54469. doi: 10.7554/eLife.54469.
26. Wang Q, Yang L, Alexander C, et al. The niche factor syndecan-1 regulates the maintenance and proliferation of neural progenitor cells during mammalian cortical development. PLoS One, 2012, 7(8): e42883. doi: 10.1371/journal.pone.0042883.
27. Rajkumar T, Amritha S, Sridevi V, et al. Identification and validation of plasma biomarkers for diagnosis of breast cancer in South Asian women. Sci Rep, 2022, 12(1): 100. doi: 10.1038/s41598-021-04176-w.
28. Sheta M, Götte M. Syndecan-1 (CD138) as a pathogenesis factor and therapeutic target in breast cancer. Curr Med Chem, 2021, 28(25): 5066-5083.
29. Nguyen TL, Grizzle WE, Zhang K, et al. Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer. Am J Clin Pathol, 2013, 140(4): 468-474.
30. Scott E, Munkley J. Glycans as biomarkers in prostate cancer. Int J Mol Sci, 2019, 20(6): 1389. doi: 10.3390/ijms20061389.
31. Wang X, He J, Zhao X, et al. Syndecan-1 suppresses epithelial-mesenchymal transition and migration in human oral cancer cells. Oncol Rep, 2018, 39(4): 1835-1842.
32. Saleh ME, Gadalla R, Hassan H, et al. The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4⁺ T cell polarization in inflammatory and non-inflammatory breast cancer patients. PLoS One, 2019, 14(5): e0217550. doi: 10.1371/journal.pone.0217550.
33. Agere SA, Kim EY, Akhtar N, et al. Syndecans in chronic inflammatory and autoimmune diseases: Pathological insights and therapeutic opportunities. J Cell Physiol, 2018, 233(9): 6346-6358.
34. Bertrand J, Bollmann M. Soluble syndecans: biomarkers for diseases and therapeutic options. Br J Pharmacol, 2019, 176(1): 67-81.
35. De Pasquale V, Pavone LM. Heparan sulfate proteoglycan signaling in tumor microenvironment. Int J Mol Sci, 2020, 21(18): 6588. doi: 10.3390/ijms21186588.
36. Qiao W, Liu H, Guo W, et al. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol, 2019, 45(7): 1132-1137.
37. Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer, 2003, 98(3): 474-483.
38. Lim GH, Tan PH, Jara-Lazaro AR, et al. Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival. Singapore Med J, 2014, 55(9): 468-472.
39. Tiemann K, Weigel MT, Alkatout I, et al. Significance of syndecan-1 expression in ductal carcinoma in situ of the breast. Anticancer Res, 2014, 34(7): 3607-3716.
40. Conklin MW, Gangnon RE, Sprague BL, et al. Collagen alignment as a predictor of recurrence after ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev, 2018, 27(2): 138-145.

Previous Article
Advances in diagnosis and treatment of pancreatic portal hypertension

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The role and research progress of Syndecan-1 in breast cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content